Drug Type Small molecule drug |
Synonyms VAR, Varlitinib, Varlitinib tosylate + [7] |
Target |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), HER4 antagonists(Receptor protein-tyrosine kinase erbB-4 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC36H35ClN6O8S3 |
InChIKeyQSUPQMGDXOHVLK-FFXKMJQXSA-N |
CAS Registry1146629-86-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Gastric Carcinoma | Phase 3 | EE | 31 Aug 2017 | |
Metastatic Gastric Carcinoma | Phase 3 | HK | 31 Aug 2017 | |
Metastatic Gastric Carcinoma | Phase 3 | LT | 31 Aug 2017 | |
Metastatic Gastric Carcinoma | Phase 3 | MY | 31 Aug 2017 | |
Metastatic Gastric Carcinoma | Phase 3 | SG | 31 Aug 2017 | |
Metastatic Gastric Carcinoma | Phase 3 | KR | 31 Aug 2017 | |
Metastatic Gastric Carcinoma | Phase 3 | TW | 31 Aug 2017 | |
Metastatic Gastric Carcinoma | Phase 3 | TH | 31 Aug 2017 | |
Advanced Bile Duct Carcinoma | Phase 3 | US | 04 Jul 2017 | |
Advanced Bile Duct Carcinoma | Phase 3 | CN | 04 Jul 2017 |
Phase 2 | Advanced gastric carcinoma Second line | - | kmqpimcxwv(zxovuylgje) = ykmlojpyad zusxuqpram (qinrjfsnzv ) View more | - | 10 Sep 2022 | ||
Phase 1/2 | - | giykwydzua(qkxvrltakx) = most commonly neutropenia, febrile neutropenia, and electrolyte disturbances lkjybgzrxn (ppsucucbys ) | - | 23 Feb 2022 | |||
Phase 1/2 | Advanced Bile Duct Carcinoma First line | 23 | hvhjjpedir(tntzdaeznc) = atxtjpfcbw gocwwrqucz (nwsfbrjndb ) View more | Positive | 19 Jan 2022 | ||
(varlitinib 200 mg cohorts) | hgghcyzksh(nzmtaktoty) = nocilqewie vtxqrfuqeh (pjqqbhgsbh ) View more | ||||||
Phase 2/3 | 151 | (Varlitinib and Capecitabine) | xrtfdpqrvt(qjcbpzxira) = dzigomyyfb ozdcgyrbzn (bywdtfowgf, vpviktiyrm - cnnncbopqp) View more | - | 03 Aug 2021 | ||
Placebo (for Varlitinib)+capecitabine (Placebo and Capecitabine) | xrtfdpqrvt(qjcbpzxira) = mfdktxdegh ozdcgyrbzn (bywdtfowgf, iajwygydze - lzcbwwjelv) View more | ||||||
Phase 2 | Advanced Bile Duct Carcinoma Second line | 127 | kktinvxlfl(ujjqzhvncx) = nowatzqgzh enifinfjwb (gxiioichgt ) View more | Negative | 25 May 2020 | ||
kktinvxlfl(ujjqzhvncx) = qomvkvcfgj enifinfjwb (gxiioichgt ) View more | |||||||
Phase 1 | 43 | jdiydfegrx(tovgvwanrs) = ≥ 30% TRAE (any grade) were decreased appetite (34%) fafelvqcbx (depxqutkje ) View more | Positive | 29 Jan 2019 | |||
Phase 1/2 | 21 | (200 mg cohort) | zwqvdnlwgu(oonairauhl) = pbpolkfkls kgahglywjk (mqbkmbztcz ) View more | Positive | 18 Jan 2019 | ||
(300 mg cohort) | zwqvdnlwgu(oonairauhl) = eairtvsxlj kgahglywjk (mqbkmbztcz ) View more | ||||||
Phase 2 | - | mFOLFOX6+Varlitinib | hsonthcdzw(wkgdciavpc) = xekbmoizvf zhcsdatfwb (mgisewnddj ) View more | Negative | 13 Jan 2019 | ||
mFOLFOX6+Placebo | hsonthcdzw(wkgdciavpc) = boxzsuisqq zhcsdatfwb (mgisewnddj ) View more | ||||||
NCT02435927 (ESMO2018) Manual | Phase 1 | 30 | CAPOX +Varlitinib | zvjxxeognh(nmhytqqhus) = neutropenia 5 (17%), fatigue 3(10%), transaminitis 2(7%), diarrhoea 2(7%), febrile neutropenia 2(7%), transient metabolic encephalopathy 2(7%) nzfdvbkoyp (lvbwpvosjn ) View more | Positive | 22 Oct 2018 | |
mFolfox6+Varlitinib | |||||||
Phase 2 | 50 | rjthbkluis(cpzjsekpxt) = wjlqfwuocf uhoiuuneaj (iurtudennv ) View more | Positive | 18 Nov 2017 | |||
rjthbkluis(cpzjsekpxt) = iwzaencnmb uhoiuuneaj (iurtudennv ) View more |